A movement to promote and conduct research on the treatment and prevention of drug-resistant tuberculosis (DR-TB) and provide access to effective cure and prevention of DR-TB throughout the world.

Over ten million people will develop tuberculosis (TB) in the world this year; over 500,000 of these will have multidrug-resistant tuberculosis (MDR-TB). Some will receive treatment. However, we know little about the best ways of treating drug-resistant TB (DR-TB) and preventing tuberculosis in people who come in contact with DR-TB patients. TB control efforts require new evidence-based knowledge about optimal treatment regimens, prophylaxis, and regimens involving new TB drugs in order to address the growing health threats of MDR-TB and extensively drug-resistant (XDR) TB.

Sign up for our monthly newsletter and review of recent literature!

To view our most recent newsletter news click here!


Upcoming Webinar

Availability of and Challenges to Resistance Testing for Second-Line Drugs, Including the New and Repurposed TB Drugs

Thursday, 24 September from 8:00-9:00 (EST)

All Resist-TB members are invited to join us for our September Webinar, sponsored by the Union’s Bacteriology and Immunology Subsection and the Union’s DR-TB Working Group


Developments in MDR-TB

New app launched for nurses to manage side effects to drug-resistant tuberculosis treatment to improve quality care for patients

Posted on 1 Jul 2020

The International Council of Nurses (ICN) today announced the launch of the ICN and Curry International TB Center (CITC) mobile app of the Nursing Guide for Managing Side Effects to Drug-resistant TB Treatment.

WHO urges countries to enable access to fully-oral drug-resistant TB treatment regimens

Posted on 17 Jun 2020

WHO releases updated guidelines for the treatment of drug-resistant TB.

U.S. FDA approves new pediatric formulation of SIRTURO® (bedaquiline) as part of combination therapy to treat children with pulmonary multidrug-resistant TB

Posted on 03 Jun 2020

NEW BRUNSWICK, NJ, May 27, 2020 — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has granted approval for a new pediatric formulation of SIRTURO® (bedaquiline). SIRTURO® is now indicated for use as part of combination therapy in the treatment of adult and pediatric patients (5 years and older and weighing at least 15 kg) with pulmonary multidrug-resistant tuberculosis (MDR‑TB). In the U.S., the medicine should be reserved for use when an effective treatment regimen cannot otherwise be provided.

MDR-TB Epidemiology Research Fellowship

Posted on 29 Apr 2020

The Harvard Medical School Blavatnik Institute of Global Health & Social Medicine is seeking candidates for a research fellowship in multidrug-resistant tuberculosis epidemiology. More information and application can be found here.

For more news, click here.